权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Developing Durable, Env-Boosted CAR T Cells for HIV Cure

开发持久的、环境增强的 CAR T 细胞用于治疗 HIV

基本信息

批准号：
10625234
负责人：
Hamideh Parhiz
金额：
$ 89.35万
依托单位：
FRED HUTCHINSON CANCER CENTER
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-11-02 至 2027-10-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10625234
关键词：
Address Alleles Animal Model Animals Antibodies Antigens Autologous B lymphoid malignancy B-Lymphocytes Bar Codes Benchmarking Berlin Biological Assay Biology CAR T cell therapy CCR5 gene CD4 Positive T Lymphocytes COVID-19 vaccination COVID-19 vaccine CRISPR/Cas technology CTLA4 gene Cancer Patient Cell Communication Cell Line Cell Therapy Cell physiology Cell surface Cells Chromosomal translocation Clinic Clinical Research Clinical Trials Clustered Regularly Interspaced Short Palindromic Repeats Data Developing Countries Disease Disease remission Dose Environment Event Experimental Designs Extracellular Domain FDA approved Future Genes Goals Graft-Versus-Tumor Induction HIV HIV therapy HIV-1 Hematologic Neoplasms Hematopoietic Neoplasms Hematopoietic stem cells Homologous Transplantation Immune Individual Infection Interruption K-562 K562 Cells Knowledge Learning Leukemic Cell Liquid substance London Lymphoma cell Macaca mulatta Malignant - descriptor Malignant Neoplasms Messenger RNA Modeling Modification Molecular Nature New York PD-1 blockade Pathway interactions Patients Persons Phase I Clinical Trials Plasma Population Study Procedures Property Public Health Recrudescences Refractory Reporting Research Design Resistance SIV Safety Series Solid Neoplasm Supplementation Supporting Cell T-Lymphocyte Technology Time Vaccines Validation Viral Viral Antigens Viral Envelope Proteins Viral Load result Viral reservoir Virus anti-PD-1 antiretroviral therapy cancer cell cell immortalization chimeric antigen receptor chimeric antigen receptor T cells clinical translation curative treatments env Gene Products exhaustion experimental study gene therapy genotoxicity high risk immune checkpoint immune checkpoint blockade in vivo interest latent HIV reservoir lipid nanoparticle manufacturing process nanoparticle delivery next generation nonhuman primate novel prevent programmed cell death protein 1 programs safety assessment single-cell RNA sequencing stable cell line success trafficking tumor viral rebound

项目摘要

PROJECT SUMMARY/ABSTRACT Modification of autologous T cells with chimeric antigen receptor (CAR) molecules was first proposed nearly 30 years ago as a therapy for people living with HIV. Since then, CAR-T cells have emerged as a potent and highly successful therapy for liquid tumors, while HIV-specific CAR-T cells have only begun to show efficacy in large animal models and clinical trials. Based on our longstanding interest in CAR-T cell therapies for HIV, we posit three primary barriers that limit the curative potential of this approach. First, low levels of HIV-1 antigen at the cell surface (namely Env protein), especially during antiretroviral therapy (ART), render latently infected cells nearly invisible to CAR-T cells and other virus-specific immune effectors. Second, the wealth of knowledge regarding cellular trafficking of the viral Env protein has yet to be thoroughly applied in the context of Env- dependent HIV cure strategies. Third, CAR-T cell persistence and function wane over time, prior to complete clearance of the latent HIV reservoir. Our groundbreaking preliminary data outlines a path to overcome these limitations. We recently reported findings in four rhesus macaques that were infected with an HIV-like virus, suppressed by ART and then infused with virus-specific CAR-T cells containing the CD4 extracellular domain (CD4CAR). To expand these potent antiviral effectors in vivo, animals were next boosted with an irradiated cell line stably expressing HIV-1 Env. Following ART treatment interruption (ATI), viral control was observed in 2 of 4 animals, consistent with robust and Env-dependent expansion of CD4CAR-T cells. The central goal of this proposal is to increase the potency and feasibility of this approach. In AIM 1, we will transition our Env boosting strategy from an immortalized cell line to an FDA-approved mRNA lipid nanoparticle (mRNA-LNP) platform, analogous to the Moderna and Pfizer/BioNTech vaccines for SARS-CoV-2. Env immunogens will be optimized for CD4CAR T cell interactions and developed as Env mRNA-LNP vaccines. In AIM 2, we will use CRISPR- Cas9 gene editing to extend the durability and function of CD4CAR-T cells. We will compare a series of CAR products that carry inactivated immune checkpoint alleles, which we hypothesize will support more durable function and efficiently clear persistent viral reservoirs. In AIM 3, we will benchmark Env mRNA-LNP and immune checkpoint gene editing strategies in our vetted nonhuman primate (NHP) model of HIV gene therapy. These experiments will feature a powerful competitive repopulation study design, providing critical information on basic CAR biology that cannot be gathered in clinical studies. Together, these aims build on what we believe to be the most promising anti-HIV cell and gene therapy approach reported to date. Our unique and highly informative NHP model of HIV persistence and CAR-T cell therapy will fill in critical gaps in knowledge regarding CAR-T cell safety and function in limited antigen environments, and facilitate clinical translation both in developed and developing nations. The lessons we learn from these studies will be applicable not only as a curative therapy for HIV-1, but for a range of diseases such as solid tumors where CAR-T cell therapies must be similarly augmented.

项目总结/文摘